News Release

For reference purposes only – Japanese version prevails in case of any discrepancy

August 7, 2025

Strategic Collaboration with Astria Therapeutics, Inc. to Develop and Commercialize Navenibart for Hereditary Angioedema in Japan

Kaken Pharmaceutical Co., Ltd. (“Kaken”, headquartered in Bunkyo-ku, Tokyo; President and Representative Director: Hiroyuki Horiuchi) and Astria Therapeutics, Inc. ("Astria", headquartered in Boston, MA, USA; Chief Executive Officer: Jill C. Milne) announced that on August 6, 2025, the companies have entered into a license agreement for the development and commercialization of Astria’s investigational drug navenibart in Japan. Navenibart is currently in development for the long-term prophylaxis of hereditary angioedema (HAE).

Under the terms of the agreement, Kaken receives an exclusive license to develop and commercialize navenibart for the long-term prophylaxis of HAE in Japan. Kaken will make an upfront payment to Astria of $16 million as well as commercial and sales milestone payments, for a total up to $16 million in addition to tiered royalties with the royalty rate as a percentage of net sales. Astria will conduct global phase 3 trials of navenibart including in Japan. Kaken will cover partial phase 3 cost and be responsible for the regulatory submission and commercialization activities in Japan.

Kaken has set expansion into new therapeutic areas as one of the core R&D policies in its Long-Term Business Plan 2031, with the aim of providing pharmaceutical products that address unmet medical needs in the future. Through its collaboration with Astria, Kaken will further strengthen its efforts to treat rare diseases and work towards providing new treatment options that contribute to longer, healthier lives.

The impact of the agreement on financial performance forecasts for FY2025 is currently under review and will promptly announce any events that are to be publicly reported.

About Navenibart
Navenibart is a monoclonal antibody inhibitor of plasma kallikrein in development for the treatment of HAE. The goal with navenibart is to provide rapid and sustained HAE attack prevention with a validated mechanism and trusted modality administered subcutaneously every 3 and 6 months. Astria aims to empower people living with HAE to live life without limitations from their disease.

About Astria Therapeutics
Astria Therapeutics (NASDAQ: ATXS) is a biopharmaceutical company, and their mission is to bring life-changing therapies to patients and families affected by allergic and immunologic diseases. Their lead program, Navenibart (STAR-0215), is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Their second program, STAR-0310, is a monoclonal antibody OX40 antagonist in clinical development for the treatment of atopic dermatitis. For more information, please visit https://astriatx.com

About Hereditary Angioedema
Hereditary angioedema is a rare genetic disorder primarily caused by a deficiency or dysfunction of the C1 esterase inhibitor (C1INH) protein. It is characterized by sudden episodes of attacks in various parts of the body, including the skin, gastrointestinal tract, and airways. Abdominal attacks can cause severe pain, while laryngeal attacks may lead to breathing difficulties and, in severe cases, can be life-threatening. Current treatments include the on-demand treatment and the prophylactic therapies to prevent attacks.

Cautionary notes regarding forward-looking statement
This release contains forward-looking statements on the Kaken group's business. They are projections based on information available at the time this release was prepared and may differ from actual results due to a variety of factors. In addition, although this release includes information related to pharmaceutical products (including those under development), these statements are not intended to be advertisement or medical advice.